Lymphoma, T-Cell Clinical Trials

31 clinical trials for Lymphoma, T-Cell across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies — RECRUITING · PHASE1
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — RECRUITING · PHASE1
• A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas — RECRUITING · PHASE1
• Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — RECRUITING · PHASE2
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma — RECRUITING · PHASE3
• JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas — RECRUITING · PHASE2
• MB-105 in Patients With CD5 Positive T-cell Lymphoma — RECRUITING · PHASE2
• PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas — RECRUITING · PHASE2
• Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies — RECRUITING · PHASE1
• Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma — RECRUITING · PHASE1
• Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma — COMPLETED · PHASE3
• IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma — COMPLETED · PHASE2
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE1
• CAR-37 T Cells in Hematologic Malignancies — COMPLETED · PHASE1
• ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy — COMPLETED · PHASE2
• Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL — OTHER · PHASE1
• ChiCGB vs BEAM in High-risk or R/R Lymphomas — OTHER · PHASE3
• SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies — OTHER · PHASE1
• Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma — OTHER · NA
• Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas — COMPLETED · PHASE2
• Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response — TERMINATED · NA
• Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma — OTHER · PHASE1
• Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma — WITHDRAWN · PHASE1
• Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies — TERMINATED · NA
• Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies — COMPLETED · PHASE2
• Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas — COMPLETED · PHASE2
• A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms — COMPLETED · PHASE1
• UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas — TERMINATED · PHASE2
• A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma — COMPLETED · PHASE2
• PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) — COMPLETED · PHASE2

Refine this search